Compounds > arsenic
Page last updated: 2024-08-26

arsenic and Leukemia, Myeloid

arsenic has been researched along with Leukemia, Myeloid in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19903 (7.50)18.7374
1990's7 (17.50)18.2507
2000's22 (55.00)29.6817
2010's8 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, K; Feng, T; Ling, S; Liu, J; Liu, P; Shan, Q; Song, P; Xiang, P; Xie, H; Xu, X; Zhang, X; Zheng, S; Zhou, L1
Chen, P; Chen, YZ; Huang, HF; Wu, JY1
Du, G; Du, Z; Geng, S; Guo, Z; Han, G; Li, Z; Lin, H; Meng, M; Yao, J; Zheng, Y1
Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H1
Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D1
Duzkale, H; Freireich, EJ; Golemovic, M; Johansen, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Verstovsek, S; Zingaro, RA1
Guo, WW; Liu, WJ1
Dashdorj, A; Ha, J; Jang, M; K R, J; Kim, SS; Kim, SY; Kim, Y; Lim, S; Min, YH; Shokat, KM; Won, H1
Zhou, J1
Gabrilove, J; Jing, Y; Liu, C; Wang, R; Waxman, S; Xia, L; Zhao, G1
Higashi, Y; Pallis, M; Russell, N; Turzanski, J1
Fung, M; Leung, KN; Mak, NK; Wong, RN1
Chaudhary, PM; Matta, H; Sun, Q1
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW1
Akhand, AA; Emi, N; Hossain, K; Kajiguchi, T; Nakashima, I; Naoe, T; Saito, H; Yamamoto, K1
Nakamura, S; Nakao, S; Ohtake, S; Okumura, H; Zhu, J1
LEBON, J; MESSERSCHMITT, J1
Boehlke, L; Frater, JL; Nabhan, C; Parmar, S; Raji, A; Riley, M; Rundhaugen, LM; Tallman, MS1
Aller, P; Amrán, D; de Blas, E; Fernández, C; Ramos, AM; Sancho, P1
Desmond, JC; Hewison, M; Hughes, SV; Koeffler, HP; Kumagai, T; O'Kelly, J; Shih, LY1
Chow, J; Huang, M; Lee, C; Lin, C; Lin, Y; Liu, C; Liu, HE1
Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W1
Bagic, A; Kessler, CM; Lupu, V; Tornatore, C1
Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH1
Akar, U; Berestein, GL; Colburn, N; Danilenko, M; Kornblau, S; Ozpolat, B; Steiner, M; Tirado-Gomez, M; Zorrilla-Calancha, I1
Preussmann, R1
Delva, L; Gabrilove, JL; Gambacorti-Passerini, C; König, A; Pandolfi, PP; Rivi, R; Scheinberg, DA; Wang, ZG; Warrell, RP1
Gallagher, RE; Huang, XJ; Klein, RS; Wiernik, PH1
Aggarwal, BB; Estey, EH; Estrov, Z; Harris, D; Kantarjian, HM; Manna, SK; Talpaz, M; Van, Q1
Chiodino, C; Donelli, A; Panissidi, T; Roncaglia, R; Torelli, G1
Bachleitner-Hofmann, T; Gisslinger, B; Gisslinger, H; Grumbeck, E1
Huang, X1
Bai, H; Lu, JH; Ou, YX; Wei, YM; Zheng, RL1
Baldus, C; Knauf, W; Rojewski, MT; Schrezenmeier, H; Thiel, E1
Gao, F; Li, H; Shi, G; Shi, X; Tang, X; Wang, Z; Yi, J1
Danieli, G1
Chou, WC; Dang, CV; Jie, C; Jones, RJ; Kenedy, AA; Trush, MA1
Prakash, VB1
Broome, JD; Li, YM1
Sears, DA1

Reviews

2 review(s) available for arsenic and Leukemia, Myeloid

ArticleYear
Arsenic trioxide: an ancient drug revived.
    Chinese medical journal, 2012, Volume: 125, Issue:19

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides; Reactive Oxygen Species

2012
P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:6

    Topics: Acute Disease; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Division; Ceramides; Child; Cyclosporine; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid; Lovastatin; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Phenotype; Protein Kinase C; Randomized Controlled Trials as Topic; Signal Transduction; Tumor Cells, Cultured

2002

Trials

1 trial(s) available for arsenic and Leukemia, Myeloid

ArticleYear
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
    Leukemia research, 2004, Volume: 28, Issue:9

    Topics: Acute Disease; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Bone Marrow Examination; Disease Progression; Drug Resistance, Multiple; Female; Glycoproteins; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome

2004

Other Studies

37 other study(ies) available for arsenic and Leukemia, Myeloid

ArticleYear
Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I.
    Cell death & disease, 2017, 11-02, Volume: 8, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Chemical and Drug Induced Liver Injury; Electron Transport Complex I; Glucose; Glycolysis; Humans; Leukemia, Myeloid; Male; Metformin; Mice; NAD; Oxidative Phosphorylation; Oxides; Reactive Oxygen Species; Rotenone

2017
The effect to IL-3Ralpha, downstream PI3k/Akt signaling of all-trans retinoic acid and arsenic trioxide in NB4 cells.
    Die Pharmazie, 2014, Volume: 69, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Interleukin-13 Receptor alpha1 Subunit; Leukemia, Myeloid; Neoplasm Proteins; Oncogene Protein v-akt; Oxides; Phosphatidylinositol 3-Kinases; RNA, Messenger; Signal Transduction; Tretinoin

2014
The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
    Journal of ethnopharmacology, 2017, Jan-20, Volume: 196

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Proliferation; Cellular Senescence; Female; Humans; K562 Cells; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Reactive Oxygen Species; Tumor Burden

2017
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
    Leukemia research, 2009, Volume: 33, Issue:7

    Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin

2009
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
    European journal of haematology, 2009, Volume: 82, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays

2009
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
    Investigational new drugs, 2010, Volume: 28, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Maximum Tolerated Dose; Membrane Potential, Mitochondrial; Mice; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Succinates

2010
[Expression of homeobox A9 in myeloid leukemia cell line HL-60 and effect of drugs on its expression].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:2

    Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia, Myeloid; Oxides; RNA, Messenger; Tretinoin

2012
Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
    Cancer research, 2012, Aug-15, Volume: 72, Issue:16

    Topics: Alcohol Oxidoreductases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Female; Gene Knockdown Techniques; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; NADPH Oxidases; Oxides; Promoter Regions, Genetic; Reactive Oxygen Species; Transcription Factor AP-1; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays

2012
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Dec-15, Volume: 18, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Catalase; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Ethacrynic Acid; Glutathione; Glutathione S-Transferase pi; Humans; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction

2012
Involvement of tumor necrosis factor (TNF-alpha) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells.
    Toxicology letters, 2002, Sep-05, Volume: 135, Issue:1-2

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Cell Division; Formazans; Interleukin-4; Leukemia, Myeloid; Mice; Oxides; Receptors, Interleukin-4; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2002
The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation.
    Blood, 2003, Mar-01, Volume: 101, Issue:5

    Topics: Acetylcysteine; Acute Disease; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Transformation, Viral; Enzyme Activation; Gene Expression Regulation, Viral; Granulocyte-Macrophage Colony-Stimulating Factor; Herpesvirus 8, Human; Humans; I-kappa B Proteins; Leukemia, Myeloid; Leupeptins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Oxides; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Recombinant Proteins; Rhadinovirus; Transcription, Genetic; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Viral Proteins

2003
Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:8

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Arsenic Trioxide; Arsenicals; Biological Availability; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Oxides; Time Factors

2002
Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1.
    Leukemia, 2003, Volume: 17, Issue:11

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Chronic Disease; Enzyme Activation; Humans; Hydrogen Peroxide; Intracellular Membranes; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myeloid; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinases; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured

2003
The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines.
    Acta haematologica, 2003, Volume: 110, Issue:1

    Topics: Acute Disease; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Cysteine Proteinase Inhibitors; Down-Regulation; Fas Ligand Protein; fas Receptor; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Membrane Glycoproteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Up-Regulation

2003
[Drug-induced aplastic myelosis; terminal acute myeloblstosis; pathogenic reflections].
    Le Sang, 1955, Volume: 26, Issue:8

    Topics: Arsenicals; Chloramphenicol; Humans; Leukemia; Leukemia, Myeloid

1955
Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.
    Blood, 2005, May-15, Volume: 105, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Activation; Glutathione; Humans; Leukemia, Myeloid; Mitochondria; Oxides; Peroxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species

2005
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Screening Assays, Antitumor; Drug Synergism; Ergocalciferols; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid; Mitochondria; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Steroid Hydroxylases; Vitamin D3 24-Hydroxylase

2005
Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:3

    Topics: Acute Disease; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Cell Count; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Drug Resistance, Neoplasm; Glutathione; Humans; Injections, Intraperitoneal; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Oxides; Stromal Cells; Treatment Failure

2006
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
    Leukemia, 2006, Volume: 20, Issue:4

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Cytarabine; DNA; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; G1 Phase; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured

2006
Iatrogenic arsenic induced Mees' lines.
    Postgraduate medical journal, 2006, Volume: 82, Issue:970

    Topics: Acute Disease; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Male; Nail Diseases; Oxides

2006
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
    Blood, 2007, Jan-15, Volume: 109, Issue:2

    Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation

2007
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Molecular cancer research : MCR, 2007, Volume: 5, Issue:1

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Granulocytes; HL-60 Cells; Humans; Leukemia, Myeloid; Macrophages; Monocytes; Oxides; Protein Transport; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Tretinoin

2007
[Skin tumors and genetic damages from arsenicals].
    Deutsche medizinische Wochenschrift (1946), 1993, May-07, Volume: 118, Issue:18

    Topics: Acute Disease; Adolescent; Arsenicals; Carcinoma, Basal Cell; Chromosome Aberrations; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Psoriasis; Skin Neoplasms

1993
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Blood, 1998, Sep-01, Volume: 92, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Division; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Melarsoprol; Mice; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins

1998
Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.
    Medical oncology (Northwood, London, England), 1999, Volume: 16, Issue:1

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Enzyme Activation; Etoposide; Humans; Leukemia, Myeloid; Oxides; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

1999
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
    Blood, 1999, Oct-15, Volume: 94, Issue:8

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenicals; Caspase 3; Caspase Inhibitors; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Humans; Interleukin-1; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Protein Tyrosine Phosphatases; Transcription, Genetic; Tumor Cells, Cultured; Tumor Stem Cell Assay

1999
Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
    Haematologica, 2000, Volume: 85, Issue:9

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Culture Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Oxides

2000
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
    British journal of haematology, 2001, Volume: 112, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Synergism; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Middle Aged; Oxides; Tumor Cells, Cultured

2001
[Regulation of arsenic trioxide-inducing apoptosis].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1999, Volume: 20, Issue:5

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Oligopeptides; Oxides; Tretinoin; Tumor Cells, Cultured

1999
Down-regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines.
    Acta pharmacologica Sinica, 2001, Volume: 22, Issue:8

    Topics: Acetylcysteine; Aminoquinolines; Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Catalase; Down-Regulation; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Oxides; Telomerase

2001
Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
    British journal of haematology, 2002, Volume: 116, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Oxides; Tumor Cells, Cultured

2002
The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide.
    Apoptosis : an international journal on programmed cell death, 2002, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Separation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Naphthoquinones; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured

2002
[Therapy of hemoblastosis. I. Elements of cytostatic and symptomatic therapy].
    Giornale di clinica medica, 1966, Volume: 47, Issue:8

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Arsenicals; Colchicine; Hodgkin Disease; Humans; Hydrazines; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma

1966
Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Mar-30, Volume: 101, Issue:13

    Topics: Antineoplastic Agents; Arsenic; Cell Line, Tumor; Cell Survival; HL-60 Cells; Humans; Leukemia, Myeloid; NADPH Oxidases; Reactive Oxygen Species; U937 Cells

2004
Arsenic and Ayurveda.
    Leukemia & lymphoma, 1994, Volume: 16, Issue:1-2

    Topics: Acute Disease; Arsenic; Female; Humans; Leukemia, Myeloid; Male; Medicine, Ayurvedic; Metals

1994
Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells.
    Cancer research, 1999, Feb-15, Volume: 59, Issue:4

    Topics: Apoptosis; Arsenic; Binding Sites; Guanosine Triphosphate; Humans; K562 Cells; Leukemia, Myeloid; Mitosis; Tubulin

1999
History of the treatment of chronic myelocytic leukemia.
    The American journal of the medical sciences, 1988, Volume: 296, Issue:2

    Topics: Arsenic; Bone Marrow Transplantation; Busulfan; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Interferons; Leukemia, Myeloid; Prognosis; Whole-Body Irradiation

1988